Canary’s work is based on decades of scientific research, cutting-edge digital technology, and a flexible platform design based on AI driven nano-technology used for targeted therapies and rapid disease diagnosis.
Our Mission
To harness the transformative power of gene therapy and AI-driven precision diagnostics to revolutionize healthcare and empower individuals to live healthier, longer lives.
Our Vision
Our vision is to transform patient care by providing targeted novel gene therapy aided by precision diagnostics for the diseases that are hardest to treat. In partnership with key opinion leaders, clinicians, regulatory experts, data scientists and commercial partners, we aim to develop the most rigorous and fastest pathway to develop our products, so patients and their doctors can use them to improve and save lives.
Raj Reddy
CEO & President, Founder
Company Overview
At Canary, we are pioneering a transformative approach to gene therapy with the aim of providing a comprehensive and lasting solution to diseases and conditions that currently have few options.
Harnessing the power novel vectors to deliver therapeutic genes and vectorized antibodies directly to the central nervous system - this dual approach hold the promise of not only halting disease progression but also restoring neurological function.
Our research include misfolded and aggregation of proteins in the central nervous system and dysregulated microRNA expressions which are linked to the underlying causes of many diseases including neurodegeneration, inflammatory diseases and cancer.
Canary is leveraging its proprietary technology platform to develop a pipeline of novel therapies and companion diagnostics to work in concert to accelerate the development and commercialization of new therapies that will transform lives.
Next Generation Gene Therapy Supported by Precision Dx
Therapeutics
Our innovative approach combines vectorized antibodies with functional transgene replacement of mutant genes to provide a comprehensive and lasting solution to neurodegenerative disorders and rare diseases .
Our proprietary vectorized antibodies are designed to specifically bind and neutralize misfolded proteins, preventing their aggregation and toxicity.
Our approach aims to restore lost neurological function by correcting the underlying genetic and proteinopathies.
Our goal is to arrest disease progression with a single administration of our dual-combination therapy, eliminating the need for lifelong medication and its associated side effects.
Diagnostics
Canary has already developed and registered a molecular POC dx platform that can detect genomic material with high sensitivity and specificity.
This platform will now be developed to rapidly and accurately measure microRNA levels in blood or other bodily fluids.
The test is enhanced with artificial intelligence to provide insights into disease progression and patient response to therapy.
The diagnostic test could also be used for rapid clinical trial enrollment and early disease diagnosis and personalized therapy.
We are committed to advancing the field of gene therapy and improving the lives of patients worldwide. Our team of scientists, engineers, and clinicians is dedicated to:
Unveiling the intricate mechanisms of disease: We are deeply invested in understanding the underlying causes of neurological disorders, paving the way for more effective treatments.
Collaborating with global partners: We foster collaborations with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of gene therapies and companion diagnostics.
Expanding our pipeline of novel therapies: We are constantly expanding our pipeline of innovative therapies to address a wide range of diseases and disorders.
Advocating for novel therapeutics: We actively engage with policymakers and patient advocacy groups to promote investment in rare diseases and gene therapy as a promising treatment option for patients in need.
Our Technology
At Canary Global Inc., we are harnessing the transformative power of gene therapy to combat debilitating diseases. Our innovative approach, combining targeted gene therapy with a multi-pronged strategy targeting miRNA, aims to halt disease progression and restore function.
With global industry experience, our team values collaboration, shares a passion for finding solutions to life’s biggest challenges and a desire to unlock the power of microRNA to transform healthcare for all.
Raj is a medical technology pioneer and entrepreneur. In addition to degrees in pharmaceutical science from the University of British Columbia, he has extensive experience in the pharmaceutical industry, medicinal chemistry, and pharmacology, with a particular focus on nanobiotechnology and survey research as well as data analysis on molecular biomarkers and related compounds. Nano-biosensors for rapid detection of molecular targets at the point of care have been a major part of his industry research. During his work on sensor development, he developed the world's first point of care molecular biomarker test for Alzheimer's disease. As CSO, he laid the groundwork for over ten patents in nano-sensor technology. Furthermore, Raj has extensive experience in global strategic management, specialty biologicals, and market access. Aside from that, he has managed risk management programs for multiple myeloma and inflammatory diseases for some of the world's largest pharmaceutical companies. The key strength of Raj is his ability to inspire high-performing teams that change the world.
Anna is an expert in global health, advocacy, and business development with more than 20 years of experience in the development of drugs and medical devices, development of partnerships, and expansion of footprints in developing markets. In the last five years, Anna helped take two companies public. She was VP for Public Affairs at Medicines for Malaria and a senior advisor to the Bill & Melinda Gates Foundation. She also advises family offices, philanthropic organizations and impact investment funds.
Dr. Guangping Gao, PhD
Senior Scientific Advisor, Gene Therapy and Rare Diseases
Senior Scientific Advisor, Gene Therapy and Rare Diseases
Guangping Gao, PhD is the Director, Li Weibo Institute for Rare Diseases Research, Director, Horae Gene Therapy Center and Viral Vector Core, Professor in Biomedical Research, UMass Chan Medical School.
Dr. Gao is an internationally recognized gene therapy researcher who has played a key role in the discovery and characterization of new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field, hugely impacting many currently untreatable human diseases. Dr. Gao has published 250+ research papers and serves as Editor of Human Gene Therapy.
Purav Badani has a Ph.D. from the Bhabha Atomic Research Centre in India and has over a decade’s worth of experience in spectroscopic techniques, breath sensors, and point-of-care devices. With expertise in molecular spectroscopy and advanced instrumental techniques in chemical analysis, he has made significant contributions to the development of laser-enabled mass-spectrometers for detecting compounds at attomolar levels. In addition, Dr. Badani is involved in research and development in the field of quantum chemistry. This includes, but is not limited to, probing the properties of biological molecules and reaction kinetics. Among his awards are a research fellowship from the Department of Atomic Energy and a gold medal from the University of Mumbai. He also has been awarded the prestigious 'Young Scientist Fellowship' by the Government of India. He has over 30 research articles published in various scientific journals to his credit.
Claire Henchcliffe, MD, D.Phil
Senior Medical Advisor, Neurological Disorders, Parkinson’s Disease
Senior Medical Advisor, Neurological Disorders, Parkinson’s Disease
Short Biography Claire Henchcliffe, M.D., D.Phil. is the Chair and Stanley van den Noort Professor of Neurology, at the University of California, Irvine. She read for her BA in Biochemistry and completed her graduate thesis at the University of Oxford in the UK. She then pursued post-doctoral training in genetics and neuroscience at the University of Cambridge, UK, and the University of California at Berkeley, California. Dr. Henchcliffe received her medical degree from the College of Physicians and Surgeons of Columbia University in New York City. She completed neurology residency and fellowship at the College of Physicians and Surgeons of Columbia University in New York City, prior to joining Weill Cornell Medical College, New York City in 2003. At Weill Cornell Medical College she developed a clinical and research program in movement disorders with a focus on clinical trials including stem cell-based therapeutics, eventually serving as Professor of Neurology and Neuroscience, and Vice Chair for Clinical Research. She served as the Weill Cornell site Principal Investigator for the NIH-funded NeuroNEXT clinical trial network and as Medical Director of the Trial Innovation Unit, for the Weill Cornell Clinical and Translational Science Center to the national NCATS-supported Trial Innovation Network. She left in 2020 to take up her position at UCI. Her current research focuses on developing new treatments for Parkinson’s disease, and she has a specific interest in the potential for data-driven personalized approaches to care, including gene- and cell-based therapies. She has been an investigator and on the steering committees for multiple clinical trials in Parkinson’s disease.
Dr Christine Duncan
Senior Scientific and Medical advisor , Rare Neurological Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
Christine is the Medical Director of Clinical Research and Clinical Development, Gene Therapy Program, Boston Children's Hospital and has been a Pediatric Hematology/Oncology Fellow at the Dana Fabor Cancer Institute for over 20 years. She is also the Director of Clinical Research and Development at, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Her research and clinical focus is on cellular therapies for rare pediatric diseases- especially neuro-metabolic disease and brain tumors. Widely published, Christine was also the clinical leader in partnership with a biotech company and MGH in the research that lead to the first FDA approved therapy for children with cerebral adrenoleukodystrophy (ALD) in the world. She is also a leader in multiple international pediatric stem cell transplant groups.
Dr Troy Lund
Senior Scientific and Medical advisor , Rare Neurological Disease
Senior Scientific and Medical advisor , Rare Neurological Disease
Troy Lund, MD, PhD, is a pediatric blood and marrow transplant physician who cares for children with adrenoleukodystrophy, leukemia and lymphoma. He sees patients at the University of Minnesota Masonic Children’s Hospital Pediatric Specialty Care Journey Clinic. Dr. Lund's research focuses on improving the outcomes for all patients undergoing blood and marrow transplantation by increasing the speed at which hematopoietic stem cells reconstitute the immune system after transplant. He is also an associate professor in the Department of Pediatrics and a faculty member in the Division of Blood and Marrow Transplantation at the University of Minnesota Medical School.
Doctor Sanjay Gandhi is a board certified interventional cardiologist with more than 15 years experience in interventional cardiology, clinical trials, service line operations, and hospital strategy in academic institutions. A member of the faculty of Case Western Reserve University in Cleveland, he also serves as the president of the Ohio Chapter of American College of Cardiology. He holds a Master of Business Administration degree with high honors from the University of Michigan. He is passionate about helping healthcare technology startups achieve full potential and clinical validation.
Join Team Canary
Enjoy the excitement of working in a dynamic environment with our dynamic business units, developing your career with us
A liquid-based detection platform that harnesses smart sensors and deep learning for early disease detection. By combining nano-sensor technology with artificial intelligence, we can detect diseases, characterize cancers, predict their response to treatment, and monitor their outcome.
Platforms
Liquid Diagnostics
Ultra-Rapid Mobile Platform
The COVID-19 Ultra-Rapid Mobile Test, offered by Canary Global Inc., is an accurate, non-invasive COVID-19 test that gives results within minutes. It offers fast test results, storage for future reference, and works securely on most modern iOS and Android devices. Under research and not available commercially.
DigiGENE™ provides real-time genetic targeting results for a range of conditions to help medical professionals accelerate therapy development and monitor patients' progress. It is a portable, precision medical tool that uses multiplex biomarkers and our DigiGENE platform. This product is under research and development and not available commercially.
An ultra-rapid, non-invasive, real-time disease detection platform based on breath.
Canary Breath Detect CV-19™
The Canary Breath Detect CV-19, available on the Breath Detect platform, detects biomarkers and patterns in the breath unique to the SARS-CoV-2 virus. Based on artificial intelligence, proprietary pattern recognition software, and new sensor technology, the innovative patent-pending platform can deliver accurate results after testing. This device is a research platform.
SentinelAI, Canary's HIPAA-compliant desktop software designed to be used at test sites and by test operators, can facilitate hardware and cloud connection, process tests, and share results.
With Canary's deep-learning platform, users can not only build the world's largest library of digital disease profiles, but also monitor global disease prevalence and spot outbreaks.
Our Canary platform can identify and characterize disease variants and mutations, providing the critical and timely information to mount a rapid response even before adverse events are learned.
